High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment
about
Progress and problems with the use of suicide genes for targeted cancer therapyCombinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapyHMGB1 in health and disease.Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors.A Double-Switch Cell Fusion-Inducible Transgene Expression System for Neural Stem Cell-Based Antiglioma Gene Therapy.A pH-sensitive heparin-binding sequence from Baculovirus gp64 protein is important for binding to mammalian cells but not to Sf9 insect cellsHigh-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell.High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistanceViral-based gene delivery and regulated gene expression for targeted cancer therapy.Baculovirus-mediated gene delivery and RNAi applications.cDNA microarray assays to evaluate immune responses following intracranial injection of baculoviral vectors in non-human primates.Gene co-expression analysis identifies common modules related to prognosis and drug resistance in cancer cell lines.Microfibers fabricated by non-covalent assembly of peptide and DNA for viral vector encapsulation and cancer therapy.Antiglioma effects of combined use of a baculovirual vector expressing wild-type p53 and sodium butyrate.An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.Baculovirus-transduced bone marrow mesenchymal stem cells for systemic cancer therapy.Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma.Development of the hybrid Sleeping Beauty: baculovirus vector for sustained gene expression and cancer therapy.Baculovirus as a Tool for Gene Delivery and Gene Therapy
P2860
Q28262370-E7B07DEE-C0F2-47B2-998A-E5E4559C1126Q33622736-747A14B5-7FE8-4937-AF0E-A108C9DD00E3Q34622835-401A122C-75B9-4848-AFED-3EB0CC7AF311Q35198414-DF8B0EAF-4A89-4136-81C4-8A57A78AE349Q35620945-687C1E34-BEDB-4B5A-B859-7532D881D016Q35666146-884E3417-87E0-4E81-BD4F-E9D61E907319Q36677697-CF9AEC7C-E8FA-4A67-88B9-8936310F3971Q37109252-8826AC7F-0CAC-4785-9E68-FC159D18996FQ37641366-D1300385-75AF-484E-9E19-D42840B86E7AQ38442441-B9A87C91-C7C5-4DFA-83EE-EB440B9EA0C1Q38734134-2941D9DD-78E4-4F6C-8BD8-F31719E7E88BQ39000867-72AC40BD-A53C-4860-BE8C-7D501D52C463Q39342512-24D2D46C-AC63-42D6-B308-9F4234A7F609Q39603933-6B7DCD67-1E98-439D-9EA8-2C5A386FDCEBQ42621989-6B80E126-C6EB-4F38-81F3-0FBBA1AE40FBQ43030477-23AD666F-9D7E-48F1-9561-DC4DEF06AF83Q43244789-47483F31-16D1-4EA8-B923-6F1D33943BA3Q44162630-E4CBE602-00E0-417D-9148-4E0B225FEE38Q57155195-7289CF88-8D8E-42A8-8E54-33906DC0EF88
P2860
High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
High mobility group box2 promo ...... argeted glioblastoma treatment
@ast
High mobility group box2 promo ...... argeted glioblastoma treatment
@en
type
label
High mobility group box2 promo ...... argeted glioblastoma treatment
@ast
High mobility group box2 promo ...... argeted glioblastoma treatment
@en
prefLabel
High mobility group box2 promo ...... argeted glioblastoma treatment
@ast
High mobility group box2 promo ...... argeted glioblastoma treatment
@en
P2093
P2860
P356
P1433
P1476
High mobility group box2 promo ...... argeted glioblastoma treatment
@en
P2093
Jerome Boulaire
Jiakai Lin
Jieming Zeng
Poonam Balani
P2860
P304
P356
10.1038/MT.2009.22
P50
P577
2009-02-24T00:00:00Z